Palladio Biosciences is a privately‑held, clinical‑stage biopharmaceutical company developing lixivaptan to treat Autosomal Dominant Polycystic Kidney Disease (ADPKD), an orphan kidney disease with limited treatment options. Lixivaptan is a potent, selective vasopressin V2 receptor antagonist that completed a Phase 2 trial (the ELiSA Study) and has been administered under expanded access to a patient who could not tolerate tolvaptan. The company is currently enrolling its first Phase 3 trial, the ALERT Study, which will treat ADPKD patients aged 18–65 who were discontinued from tolvaptan for liver chemistry abnormalities or signs of liver toxicity, with treatment up to 58 weeks. The primary objective of ALERT is to assess the liver safety of lixivaptan in this patient population. Palladio states the Series B proceeds will fund the ALERT Study and advance company operations. The company emphasizes the unmet medical need in ADPKD and the potential of lixivaptan to offer a therapeutic alternative to patients who cannot tolerate the only currently approved U.S. therapy, tolvaptan.

Total raised

$20M

Funding rounds

1

Latest round

Series B

Latest activity

Sep 2020